A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

This study is comparing several immunotherapy combinations for people with advanced kidney cancer (renal cell carcinoma) who have never received treatment before. It is testing whether different combinations of immune-boosting drugs can improve outcomes compared to the current standard. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic kidney cancer with a clear cell type - You have never received any systemic (whole-body) treatment for kidney cancer - Your cancer can be measured on imaging scans - You are well enough to participate (Karnofsky score of 70% or higher) - You have adequate organ function **You may NOT be eligible if...** - You have already received treatment (including adjuvant or neoadjuvant therapy) for kidney cancer - Your cancer has spread to the brain and is not controlled - You have an active autoimmune disease requiring immune-suppressing medication - You have serious lung inflammation or inflammatory bowel disease Talk to your doctor to see if this trial is right for you.